Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of an IM-induced pityriasis rosea (PR)-like cutaneous eruption. Patients developed an erythematous, slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.
Brazzelli
Valeria
V
Department of Human and Hereditary Pathology, Institute of Dermatology, Pavia, Italy. vbrazzelli@libero.it
Prestinari
Francesca
F
Roveda
Elena
E
Barbagallo
Tania
T
Bellani
Eleonora
E
Vassallo
Camilla
C
Orlandi
Ester
E
Passamonti
Francesco
F
Borroni
Giovanni
G
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D017515:Pityriasis Rosea / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate